- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT02253121
Glucose Control During Glucocorticoid Therapy in Acute Exacerbation of Chronic Obstructive Pulmonary Disease (GluCon-COPD)
Randomized, Double-blind, Placebo-controlled Trial on the Effectiveness and Safety of Dapagliflozin for Blood Glucose Control During Glucocorticoid Treatment for Acute Exacerbation COPD
Purpose of this study is to treat glucocorticoid induced hyperglycemia due to glucocorticoid pulse therapy in a efficacious, safe and convenient way. Patients with acute exacerbation of COPD treated with glucocorticoid pulse therapy and at high risk for glucocorticoid induced hyperglycemia (defined as known type 2 DM or glucose > 10mmol/l at admission) will be randomized to treatment of dapagliflozin or placebo orally, once daily.
Percentage of time within glucose target range (3,9-10 mmol/l) and incidence rate of hypoglycemia will be compared between dapagliflozin group and placebo group.
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
Rationale: Patients hospitalized for COPD exacerbation treated with high dose glucocorticoids, frequently develop hyperglycaemia. Currently, sliding scale insulin is often used to bridge such episodes. However, sliding scale insulin is patient unfriendly, does not reduce glycaemic excursion nor glycaemic variability. In contrast, pharmacologic inhibition of the sodium glucose transporter-2 (SGLT-2) can be given as an oral agent and is likely to result in better glucose control with lower risk of hypoglycaemia Objective: glucose control and safety (risk of hypoglycaemia). Secondary objectives are patient satisfaction, other safety outcomes and other parameters of glucose control Study design: Double-blind placebo controlled intervention study Study population: Patients hospitalized for an exacerbation of chronic obstructive lung disease who are treated with high dose glucocorticoids.
Intervention: One group receives once daily a 10mg tablet of dapagliflozin and the other group receives once daily a placebo tablet as add on to their prestudy glucose-lowering medication. Both groups will be treated with glucose lowering escape medication if required.
Main study parameters/endpoints: Glucose control is measured as the average time spent within target range in each patient. Safety is measured as the incidence rate of hypoglycaemia during study follow-up.
Nature and extent of the burden and risks associated with participation, benefit and group relatedness: The burden of participation consists of the extra capillary glucose measurements that will be done 3-4 times daily and wearing a coin size glucose sensor. Furthermore, patients have to fill out a treatment satisfaction questionnaire. There will be no extra site visits for participants.
Dapagliflozin (experimental group) carries a risk of hypoglycaemia, especially for patient who have concomitant therapy with insulin or sulfonylurea derivatives. Patients will be instructed to anticipate, and if required dosing of glucose lowering therapy will be adjusted. Furthermore, dapagliflozin carries an increased risk of urogenital infections, increased haematocrit and LDL cholesterol.
Study Type
Enrollment (Actual)
Phase
- Phase 4
Contacts and Locations
Study Locations
-
-
-
Amsterdam, Netherlands, 1066 EC
- Slotervaart Hospital
-
Amsterdam, Netherlands
- OLVG West
-
Hoofddorp, Netherlands
- Spaarne Ziekenhuis
-
Zwolle, Netherlands
- Isala
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Informed consent
- Hospitalization due to AECOPD
- Treatment with ≥30mg prednisone daily or equivalent dose of glucocorticoid for AECOPD
- An expected duration of glucocorticoid treatment of 3-14 days at study entry
- Known type 2 diabetes or glucose ≥ 10 mmol/l at admission
Exclusion Criteria:
- High dose glucocorticoid treatment started ≥7 days before study entry
- Need for ICU admission
- Chronic kidney disease stage G3 (glomerular filtration rate <60ml/minute)
- Recurrent genital or urinary tract infection
- Current use of any SGLT-2 inhibiting agent
- Suspected volume depletion
- Congestive heart failure functional classification NYHA class IV/IV or instable heart failure
- Acute stroke within 2 months before inclusion.
- Recent cardiovascular event: acute coronary syndrome, hospitalisation for unstable angina or coronary revascularisation within 2 months before inclusion
- Suspected liver disease, confirmed by AST/ALT > 3x ULN or bilirubin >2.0mg/dl (34.2 μmol/l) or serologically proven infection with hepatitis B or hepatitis C
- Pregnancy or breast feeding
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Quadruple
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Dapagliflozin + sliding scale insulin.
Treatment with dapagliflozin 10mg once daily orally.
Treatment will start as soon as possible after initation of glucocorticoid pulse therapy for acute exacerbation COPD and will end when pulse therapy is finished (expected duration 10-14 days).
In case of persistent glucose levels > 12 mmol/l, subjects will receive escape treatment with sliding scale insulin.
|
Dapagliflozin 10mg during glucocorticoid therapy for acute exacerbation COPD
Other Names:
Sliding scale insulin with short acting insulin based on current glucose levels
Other Names:
|
Placebo Comparator: Placebo + sliding scale insulin
Treatment with placebo once daily orally.
Treatment will start as soon as possible after initation of glucocorticoid pulse therapy for acute exacerbation COPD and will end when pulse therapy is finished (expected duration 10-14 days).
In case of persistent glucose levels > 12 mmol/l, subjects will receive escape treatment with sliding scale insulin.
|
Sliding scale insulin with short acting insulin based on current glucose levels
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Glucose control
Time Frame: 2nd till 7th day of treatment
|
% time within target range (3.9-10 mmol/l)
|
2nd till 7th day of treatment
|
Risk of hypoglycemia
Time Frame: Randomisation till end of study (expected duration of 12 days)
|
Incidence rate of hypoglycaemic events
|
Randomisation till end of study (expected duration of 12 days)
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Patient satisfaction
Time Frame: During hospital stay (expected average of 9 days)
|
Diabetes treatment satisfaction questionnaire for inpatients
|
During hospital stay (expected average of 9 days)
|
Clinical outcomes
Time Frame: During hospital stay (expected average of 9 days)
|
Duration of hospitalisation, need for treatment escalation, incidence (re-)infections, change in body weight and blood pressure.
|
During hospital stay (expected average of 9 days)
|
Safety
Time Frame: Randomisation till end of study (expected duration of 12 days)
|
incidence rate of asymptomatic hypoglycaemia, incidence adverse events of special interest (genital infections, urinary tract infections, renal impairment, liver injury and breast-, bladder- and prostate cancer), incidence of other adverse events.
|
Randomisation till end of study (expected duration of 12 days)
|
Collaborators and Investigators
Sponsor
Investigators
- Principal Investigator: Victor Gerdes, MD, PhD, Slotervaart Hospital
Publications and helpful links
Helpful Links
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- NL49690.048.14
- 2014-001877-15 (EudraCT Number)
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Hyperglycemia Steroid-induced
-
Imperial College LondonNot yet recruitingSteroid-Induced Diabetes | Steroid Induced HyperglycemiaUnited Kingdom
-
Slotervaart HospitalCompletedHyperglycemia Steroid-inducedNetherlands
-
University of CopenhagenUnknownSurgery--Complications | Hyperglycemia Stress | Hyperglycemia Steroid-inducedDenmark
-
Cook County HealthCompletedDiabetes | Hyperglycemia Steroid-induced
-
Northwestern UniversityTerminatedInsulin Resistance, Diabetes | Hyperglycemia Steroid-inducedUnited States
-
AmgenCompletedSteroid-induced Osteopor, Glucocorticoid-induced OsteporDenmark, Netherlands, Belgium, United States, Czechia, Poland, Russian Federation, Hungary, Korea, Republic of, Spain, Germany, France, Canada, Argentina, Colombia, Mexico
-
Christiane HaaseRecruitingAsthma | Chronic Rhinosinusitis With Nasal Polyps | Chronic Rhinosinusitis Without Nasal Polyps | Steroid-Induced Osteopenia (Diagnosis) | Steroid-Induced Diabetes | Steroid-Induced HyperglycemiaDenmark
-
National Centre of Ophthalmology named after academician...Aeon Astron Europe B.V.CompletedSteroid Induced GlaucomaAzerbaijan
-
Peking Union Medical College HospitalCompletedGlucocorticoid-induced Hyperglycemia
Clinical Trials on Dapagliflozin
-
Dong-A ST Co., Ltd.CompletedType2 DiabetesKorea, Republic of
-
AstraZenecaRecruitingLiver CirrhosisSpain, Denmark, Germany, United States, China, Australia, Belgium, Netherlands, Switzerland, Austria, Taiwan, Canada, Czechia
-
AstraZenecaBristol-Myers SquibbCompletedType 2 Diabetes MellitusUnited Kingdom
-
AstraZenecaCompletedType 1 Diabetes MellitusJapan
-
AstraZenecaNot yet recruitingChronic Kidney DiseaseUnited States, Austria, Italy, Spain, Canada, Malaysia, Taiwan, Poland, Bulgaria
-
AstraZenecaCompletedType 1 Diabetes MellitusJapan
-
AstraZenecaCompletedChronic Kidney DiseaseUnited States
-
Daewoong Pharmaceutical Co. LTD.Active, not recruitingGlucose Metabolism Disorders | Diabetes Mellitus, Type 2 | Diabetes Mellitus | Endocrine System Diseases | Metabolic DiseaseChina
-
Hiddo Lambers HeerspinkAstraZenecaUnknownChronic Kidney Diseases | ProteinuriaCanada, Malaysia, Netherlands
-
AstraZenecaCompletedHealthy Subjects in Fasted and Fed StateBrazil